Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Robert Mittra (NPI 1699764456)

Field	Value
Entity Type	Individual
Organization	Robert Mittra
Address	7760 France Ave S
City	Minneapolis
State	MN
ZIP	55435
Taxonomy	Ophthalmology Physician
NPI Enumerated	October 14, 2005

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider’s lifetime Medicare footprint is concentrated: total Medicare revenue is $3.1M and there is no Medicaid billing on file, so the practice effectively operates as a Medicare-focused provider rather than a mixed Medicaid/Medicare practice. The absence of any Medicaid claims means payer-mix analysis should treat this entity as single‑payer (Medicare) when assessing contracting or network value.

Revenue is highly concentrated in a small set of injection codes: the precomputed top 3 Medicare codes by revenue account for 76.6% of this provider’s total Medicare revenue, with J0178 alone representing 47.7% of Medicare revenue, Q5128 contributing 21.2%, and J2778 contributing 7.7%. This concentration indicates that anti‑VEGF and related intravitreal drug administration drive the majority of billings and payments.

The procedure mix indicates a retina-focused ophthalmology operation: dominant injectable drug codes (J0178, Q5128, J2778, J2777) combined with high-volume retinal imaging (92134 with 3K claims, $88.8K revenue) and fluorescein angiography (92235, 207 claims, $22.6K revenue) point to routine intravitreal therapy workflows supported by diagnostic OCT and angiography services. The presence of retinal surgery codes—67041 (28 claims, $24.6K), 67108 (18 claims, $16K), and 67113 (13 claims, $13.6K)—also shows the practice performs some surgical retina interventions in addition to office-based injections.

Competitive standing on injection codes is mixed: J0178 ranks #457 of 3204 providers nationally (86th percentile; typical, unremarkable volume), indicating an above‑average but not dominant national position for aflibercept injections. Q5128 ranks #33 of 373 providers (91th percentile; typical, unremarkable volume), signaling relatively high national activity among providers using this ranibizumab biosimilar, while J2778 ranks #339 of 1208 (72th percentile; typical, unremarkable volume), reflecting more modest standing for that ranibizumab formulation.

Diagnostic and exam volumes are notable outliers: 92134 is an extreme outlier nationally (ranks #427 of 26868, 98th percentile; far above typical volume) with 3K claims and $88.8K revenue, indicating unusually heavy use of retinal OCT imaging. Supporting that high imaging intensity, routine exam code 92014 shows 895 claims, $81.4K revenue and ranks #2097 of 35415 (94th percentile; notably above typical national volume), consistent with a busy ophthalmology practice that pairs imaging with treatment.

Payer/payment profile within Medicare shows variation by drug and code: J0178 carries a relatively high average paid/claim ($692 avg paid/claim, $1.5M revenue from 2.2K claims), while other injectables show lower averages (Q5128 $217 avg paid/claim, $665.8K revenue from 3.1K claims; J2777 $29 avg paid/claim, $154.9K revenue from 5.3K claims). These differences highlight that the provider’s revenue mix depends on both drug selection and volume—high claim counts for some codes do not necessarily translate into commensurate revenue without higher per‑claim payments.

Use of unclassified biologics and other injectables is material but secondary: J3590 (278 claims, $66.7K revenue, ranks #139 of 631, 78th percentile) and J9035 (78 claims, $4.1K revenue) indicate additional biologic administration beyond the primary anti‑VEGF agents, which may reflect mixed product use or billing of ancillary biologic supplies. These ancillary biologic billings supplement the practice’s injection revenue but do not approach the top three codes in revenue share.

The provider is an established practitioner: NPI enumerated (registered) 2005-10-14 (~21 years ago), signaling long tenure in the Medicare program. That longevity, combined with concentrated injection and imaging volumes, suggests a well‑established retina/medical ophthalmology practice rather than a recently entered or transient billing pattern.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	2,160	$690	$1.5M
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	3,070	$220	$665.8K
J2778	Injection, ranibizumab, 0.1 mg	1,300	$190	$243.1K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,900	$90	$174.8K
J2777	Injection, faricimab‑svoa, 0.1 mg	5,340	$30	$154.9K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,960	$30	$88.8K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	900	$90	$81.4K
J3590	Unclassified biologics	280	$240	$66.7K
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	200	$170	$33.7K
67041	In this procedure, the provider removes scar tissue from the retinal membrane that obscures vision. He removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical…	30	$880	$24.6K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Robert Mittra — 3 of 21 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	7	40	580	$690	$743.4K
J2777	16	20	6,120	$30	$411.1K
Q5128	3	20	1,410	$220	$393.8K
J2778	3	20	500	$180	$121K
J3590	3	10	220	$230	$73.7K
67028	9	80	420	$90	$64.8K
Q5124	4	10	200	$170	$49.2K
67113	2	10	10	$1,440	$46.2K
67108	4	10	10	$1,230	$34.4K
67041	3	10	20	$1,090	$25.1K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Robert Mittra, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Fairview Health Services	MN	General Acute Care Hospital	$0	$90.4M
Regions Hospital	MN	General Acute Care Hospital	$0	$44.4M
Fairview Express Care	MN	Specialist	$0	$33.1M
Fairview Health Services	MN	General Acute Care Hospital	$0	$30M
Vitreoretinal Surgery PLLC	MN	Ophthalmology Physician	$0	$27.8M
Fairview Health Services	MN	Emergency Medicine Physician	$0	$26.6M
Fairview Health Services	MN	General Acute Care Hospital	$0	$17.2M
Regions Hospital	MN	Emergency Medicine Physician	$0	$15.1M
Fairview Express Care	MN	General Practice Physician	$0	$11.4M
Maple Grove Hospital Corporation	MN	General Acute Care Hospital	$0	$7.6M

Nearby Providers

Other providers in the same ZIP code as Robert Mittra, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Emergency Physicians Professional Association	MN	Emergency Medicine Physician	$0	$72.7M
Professional Resource Network - Prn - Corporation	MN	Home Health Agency	$0	$12.4M
Virtual Radiologic Professionals, LLC	MN	Diagnostic Radiology Physician	$0	$11.3M
Mental Health Systems PC	MN	Psychologist	$0	$11M
Premier Obgyn Of Minnesota PLLC	MN	Obstetrics & Gynecology Physician	$0	$7M
Noran Neurological Clinic P.A.	MN	Specialist	$0	$6M
Nura Surgical Center LLC	MN	Ambulatory Surgical Clinic/Center	$5.3M	$581.7K
Southdale Pediatric Associates, Ltd	MN	Multi-Specialty Clinic/Center	$0	$5.3M
David Parke	MN	Ophthalmology Physician	$4.8M	$0
Sundeep Dev	MN	Ophthalmology Physician	$4.5M	$0

Robert Mittra — Billing Profile & Reimbursement Data

Sign up for Robert Mittra — Billing Profile & Reimbursement Data policy alerts

Robert Mittra — Billing Profile & Reimbursement Data

Sign up for Robert Mittra — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References